25. November 2021 – The Confederation has concluded a contract with the company MSD Merck Sharp & Dohme AG Switzerland for the reservation of a promising medicinal product against the coronavirus (SARS-CoV-2). The medicine in question is the antiviral medicine Molnupiravir.

For more information, see here.